ZVRA Earnings & Financial Statements
Zevra Therapeutics, Inc.
$10.70
+$0.71(+7.11%)
43
Overall
80
Value
--
Tech
50
Quality
Market Cap
$593.24M
Volume
1.98M
52W Range
$8.01 - $15.04
Target Price
$25.25
ZVRA earnings and financial statements: Zevra Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ZVRA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $106.47M | $23.60M | $27.46M | $10.16M | $28.65M |
| Cost of revenue | $16.48M | $7.42M | $2.17M | $222.0K | $2.06M |
| Operating income | -$62.94M | -$87.00M | -$49.60M | -$24.90M | $7.73M |
| EBITDA | $99.31M | -$75.85M | -$43.54M | -$7.86M | -$7.89M |
| Net income | $83.23M | -$105.51M | -$46.05M | -$9.11M | -$8.55M |
| EPS (diluted) | $1.35 | $-2.28 | $-1.30 | $-1.20 | $-2.11 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $284.73M | $178.13M | $172.33M | $115.34M | $132.94M |
| Total liabilities | $130.07M | $138.46M | $110.46M | $40.22M | $5.82M |
| Shareholders’ equity | $154.66M | $39.67M | $61.86M | $75.12M | $127.12M |
| Cash and equivalents | $62.41M | $33.78M | $43.05M | $65.47M | $112.35M |
| Long-term debt | $62.79M | $59.88M | $5.52M | $13.64M | $1.23M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$1.60M | -$69.67M | -$33.53M | -$36.38M | $10.44M |
| Capital expenditure | -$387.0K | -$6.00M | -$296.0K | -$93.0K | -$102.0K |
| Free cash flow | -$2.43M | -$75.67M | -$33.83M | -$18.81M | $10.34M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ZVRA | $10.70 | +7.1% | 1.98M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Zevra Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW